Zobrazeno 1 - 10
of 15
pro vyhledávání: ''
Autor:
Michael S. Saag, David Wong, Rachel Baden, Liyun Ni, John G. McHutchison, Anne F Luetkemeyer, Douglas T. Dieterich, Curtis Cooper, Mark S. Sulkowski, Paul E. Sax, E.J. Gane, Javier O Morales-Ramirez, Susanna Naggie, Phillip S. Pang, William J. Towner, Peter Ruane, Dushyantha Jayaweera, Catherine A.M. Stedman, Luisa M. Stamm, Kimberly A. Workowski, Hadas Dvory-Sobol, Jorge Santana-Bagur, Polina German, Amy E. Colson, Norbert Bräu, Jenny C. Yang, Pablo Tebas, Kristen M. Marks
Publikováno v:
New England Journal of Medicine. 373:705-713
Effective treatment for hepatitis C virus (HCV) in patients coinfected with human immunodeficiency virus type 1 (HIV-1) remains an unmet medical need.We conducted a multicenter, single-group, open-label study involving patients coinfected with HIV-1
Autor:
Xavier Forns, B. Bernstein, Eric M. Yoshida, Thomas Berg, Stefan Zeuzem, Mitchell L. Shiffman, Roger Trinh, Barbara Da Silva-Tillmann, Heiner Wedemeyer, Christophe Hézode, Thomas Podsadecki, Christine Collins, Kosh Agarwal, Campbell Andrew L, Sandra S. Lovell, Kris V. Kowdley, Fred Poordad
Publikováno v:
Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de la UB
Universidad de Barcelona
instname
Dipòsit Digital de la UB
Universidad de Barcelona
Background Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased toxic effects in patients who also have cirrhosis. We evaluated the interferon-free combination of the protease inhibitor A
Autor:
Nezam, Afdhal, K Rajender, Reddy, David R, Nelson, Eric, Lawitz, Stuart C, Gordon, Eugene, Schiff, Ronald, Nahass, Reem, Ghalib, Norman, Gitlin, Robert, Herring, Jacob, Lalezari, Ziad H, Younes, Paul J, Pockros, Adrian M, Di Bisceglie, Sanjeev, Arora, G Mani, Subramanian, Yanni, Zhu, Hadas, Dvory-Sobol, Jenny C, Yang, Phillip S, Pang, William T, Symonds, John G, McHutchison, Andrew J, Muir, Mark, Sulkowski, Paul, Kwo, Ziad, Younes
Publikováno v:
New England Journal of Medicine. 370:1483-1493
Effective treatment for hepatitis C virus (HCV) genotype 1 infection in patients who have not had a sustained virologic response to prior interferon-based therapy represents an unmet medical need.We conducted a phase 3, randomized, open-label study i
Autor:
Florence Abravanel, Sophie Hillaire, Louis d’Alteroche, Vincent Mallet, Jacques Izopet, Lionel Rostaing, Audrey Coilly, Anne-Marie Roque-Afonso, Sébastien Dharancy, Maryvonne Hourmant, Michael Bismuth, Nassim Kamar, Anne Minello, Jérôme Dumortier, Lionel Couzi, Matthias Büchler, Pascal Lebray, Valérie Garrigue, Stanislas Pol, Simona Tripon, Sylvie Radenne
Publikováno v:
New England Journal of Medicine. 370:1111-1120
Background There is no established therapy for hepatitis E virus (HEV) infection. The aim of this retrospective, multicenter case series was to assess the effects of ribavirin as monotherapy for solid-organ transplant recipients with prolonged HEV vi
Autor:
Tami Pilot-Matias, David R. Nelson, Mark S. Sulkowski, Wangang Xie, Paul Y. Kwo, George Liossis, Fred Poordad, Gregory T. Everson, Amit Khatri, Lois Larsen, Stefan Zeuzem, Graham R. Foster, Kris V. Kowdley, B. Bernstein, Eric Lawitz, Daniel E. Cohen, Thomas Podsadecki
Publikováno v:
New England Journal of Medicine. 370:222-232
An interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the nonnucleoside polymerase inhibitor ABT-333, and ribavirin showed efficacy against the hepatitis C virus (HCV) in a pilot study involving patients with HC
Autor:
Stuart C. Gordon, David L. Wyles, Aasim Sheikh, Maribel Rodriguez-Torres, John McNally, Sarah Arterburn, Robert H. Hyland, M. Davis, Eric Lawitz, Tarek Hassanein, G. Mani Subramanian, Kris V. Kowdley, Zeid Kayali, Ira M. Jacobson, William T. Symonds, Diana M. Brainard, Deyuan Jiang, Michael Schultz, Alessandra Mangia, K. Rajender Reddy, L. Nyberg, Edward Gane, John G. McHutchison, Zobair M. Younossi
Publikováno v:
New England Journal of Medicine. 368:1878-1887
In phase 2 trials, the nucleotide polymerase inhibitor sofosbuvir was effective in previously untreated patients with chronic hepatitis C virus (HCV) genotype 1, 2, or 3 infection.We conducted two phase 3 studies in previously untreated patients with
Autor:
Catherine A.M. Stedman, M.M. Berrey, Evguenia S. Svarovskaia, William T. Symonds, Xiao Ding, Edward Gane, R. Hindes, Robert H. Hyland
Publikováno v:
New England Journal of Medicine. 368:34-44
The standard treatment for hepatitis C virus (HCV) infection is interferon, which is administered subcutaneously and can have troublesome side effects. We evaluated sofosbuvir, an oral nucleotide inhibitor of HCV polymerase, in interferon-sparing and
Autor:
Claudia Martorell, Anna S. Lok, Eric Lawitz, Vinod K. Rustgi, Gregory T. Everson, Claudio Pasquinelli, Tong Guo, Timothy Eley, Fiona McPhee, Anna Persson, Robert Reindollar, Reem Ghalib, Megan Wind-Rotolo, Dennis M. Grasela, Kurt Zhu, David F. Gardiner, Dessislava Dimitrova
Publikováno v:
New England Journal of Medicine. 366:216-224
Patients with chronic hepatitis C virus (HCV) infection who have not had a response to therapy with peginterferon and ribavirin may benefit from the addition of multiple direct-acting antiviral agents to their treatment regimen.This open-label, phase
Autor:
Sherman, Kenneth E, Flamm, Steven L, Afdhal, Nezam H, Nelson, David R, Sulkowski, Mark S, Everson, Gregory T, Fried, Michael W, Adler, Michael, Reesink, Hendrik W, Martin, Marie, Sankoh, Abdul J, Adda, Nathalie, Kauffman, Robert S, George, Shelley, Wright, Christopher I, Poordad, Fred, ILLUMINATE Study Team, the, Van Vlierberghe, Hans
Publikováno v:
NEW ENGLAND JOURNAL OF MEDICINE
New England journal of medicine, 365(11), 1014-1024. Massachussetts Medical Society
New England journal of medicine, 365(11), 1014-1024. Massachussetts Medical Society
Background : Patients with chronic infection with hepatitis C virus (HCV) genotype 1 often need 48 weeks of peginterferon-ribavirin treatment for a sustained virologic response. We designed a noninferiority trial (noninferiority margin, -10.5%) to co
Autor:
John G, McHutchison, Gregory T, Everson, Stuart C, Gordon, Ira M, Jacobson, Mark, Sulkowski, Robert, Kauffman, Lindsay, McNair, John, Alam, Andrew J, Muir, Z, Younossi
Publikováno v:
New England Journal of Medicine. 360:1827-1838
Background Current therapy for chronic hepatitis C virus (HCV) infection is effective in less than 50% of patients infected with HCV genotype 1. Telaprevir, a protease inhibitor specific to the HCV nonstructural 3/4A serine protease, rapidly reduced